Art

J-GLOBAL ID：201202220899875505   Reference number：12A0915910

Perception of Physicians, Pharmacists and Pharmaceutical Industries about Information in Package Inserts in Japan

日本の医薬品添付文書の情報に関する医師,薬剤師,製薬企業の認識

Author (10)： SAITO Mitsuo (Teikyo Heisei Univ., Chiba, JPN) ,  SAITO Mitsuo (National Inst. Health Sci., Tokyo, JPN) ,  SAITO Mitsuo (Musashino Univ., Tokyo, JPN) ,  YOSHIDA Lucia S. (Musashino Univ., Tokyo, JPN) ,  HAYASHI Yuzuru (Teikyo Heisei Univ., Chiba, JPN) ,  SAI Kimie (National Inst. Health Sci., Tokyo, JPN) ,  TAKANO-OHMURO Hiromi (Musashino Univ., Tokyo, JPN) ,  YAJIMA Takehiko (Health Vigilance Res. Organization, Tokyo, JPN) ,  SAWADA Yasufumi (Univ. Tokyo, Tokyo, JPN) ,  HASEGAWA Ryuichi (National Inst. Health Sci., Tokyo, JPN)
Material： 医薬品情報学  (Japanese Journal of Drug Informatics)
Volume： 14  Issue： 1  Page： 2-13  Publication year： May. 31, 2012 
JST Material Number： L5202A  ISSN： 1345-1464  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： human ,...
Semi thesaurus term： update ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=12A0915910&from=J-GLOBAL&jstjournalNo=L5202A") }}

JST classification (1)： Pharmaceutical affairs,pharmaceutical practice  (GU01020R)

Reference (21)：

• 1) Ministry of Health and Welfare. Guidelines for package inserts for prescription drugs, notification no. 59 of Pharmaceutical Affairs Bureau. 1997; Tokyo: Ministry of Health and Welfare.
• 2) Ministry of Health and Welfare. Guidelines for package inserts for prescription drugs, notification no. 606 of Pharmaceutical Affairs Bureau. 1997; Tokyo: Ministry of Health and Welfare.
• 3) Ministry of Health and Welfare. Guidelines for precautions for prescription drugs, notification no. 607 of Pharmaceutical Affairs Bureau. 1997; Tokyo: Ministry of Health and Welfare.
• 4) Ministry of Health and Welfare. A report on investigation of side effects of sorivudine: deaths caused by interactions between sorivudine and 5-FU prodrugs. Pharmaceutical Affairs Bureau 1994; Tokyo: Ministry of Health and Welfare.
• 5) Po A L, Zhang W Y. What lessons can be learnt from withdrawal of mibefradil from the market ?. Lancet 1998; 351: 1829-30.

Terms in the title (5)： 日本 ,  医薬品添付文書 ,  医師 ,  薬剤師 ,  製薬企業